Bihua Chen's Net Worth

$1.18 Billion

Estimate Recalculated Feb 28, 2024 05:06PM EST

Who is Bihua Chen?

Bihua Chen has an estimated net worth of $1.18 Billion. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., MoonLake Immunotherapeutics, Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, and EyePoint Pharmaceuticals, Inc..

SEC CIK

Bihua Chen's CIK is 0001599214

Past Insider Trading and Trends

2023 was Bihua Chen's most active year for acquiring shares with 69 total transactions. Bihua Chen's most active month to acquire stocks was the month of May. 2021 was Bihua Chen's most active year for disposing of shares, totalling 16 transactions. Bihua Chen's most active month to dispose stocks was the month of October. 2023 saw Bihua Chen paying a total of $284,755,164.62 for 17,676,566 shares, this is the most they've acquired in one year. In 2021 Bihua Chen cashed out on 17,518,032 shares for a total of $3,753,000.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Snapshot price: $25.38

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+103.45%
750K
$19.00
$14,250,000.00
1.48M
Feb 2
Form 4
+63.89%
282.63K
$32.24
$9,111,940.74
725K
Jan 26
Form 3
0
0
No matching records found

Turning Point Therapeutics, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Form 4
+0.75%
23.27K
$2.19
$51,061.63
3.12M
May 13 - May 14
Form 3
0
0
Form 4
+14.82%
400K
$18.00
$7,200,000.00
3.1M
Apr 22
No matching records found

Vigil Neuroscience, Inc. (VIGL) Snapshot price: $2.85

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
616.79K
616.79K
Jan 11
Form 3
0
0
No matching records found

Prometheus Biosciences, Inc. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.22M
$19.00
2.22M
Mar 16
Form 3/A
0
0
Form 3
0
0
No matching records found

Ambrx Biopharma, Inc. (AMAM) Snapshot price: $27.78

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+13.17%
1.31M
$6.99
$9,139,541.93
11.23M
Oct 23
No matching records found